InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,468.47
(
-0.02%
)
US TECH 100
19,185.60
(
0.05%
)
Dow Jones
39,152.06
(
0.10%
)
Brent Oil
84.40
(
0.25%
)
Bitcoin
61,002.97
(
-1.31%
)
Post# of 252370
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 833
Posts 119921
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: DewDiligence post# 174512

Monday, 08/24/2020 10:16:31 AM

Monday, August 24, 2020 10:16:31 AM

Post# of 252370
ONTX—(-72%)—fails phase-3 MDS again:

http://www.globenewswire.com/news-release/2020/08/24/2082504/0/en/Onconova-Therapeutics-Announces-Topline-Results-from-the-Pivotal-Phase-3-INSPIRE-Trial.html

Results of INSPIRE demonstrated that in the intent-to-treat analysis patients randomized to IV rigosertib achieved overall survival of 6.4 months, versus 6.3 months for PC (p=0.33) in the overall HR-MDS population. Overall survival in the pre-specified VHR-MDS subgroup of patients was also not significantly different between the two study arms.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up